<DOC>
	<DOC>NCT02521506</DOC>
	<brief_summary>Diabetes mellitus is one of the most prevalent disease in the western world. The control of glucose levels has a big impact in the prevention of diabetes complications. The measure of glucose levels in capillary blood with glucometers is the gold standard to measure and control the glucose levels. Nowadays the glucometers become to more precise and sophisticated devices. One of the most notables advance is the inclusion of software that cam predicts glucose trends. This software has not be tested in routine clinical practice.</brief_summary>
	<brief_title>Clinical Efficacy of OneTouch® Verio™IQ Meter</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>Patient diagnosed with diabetes mellitus 1 or 2 Treatment with insulin regimen during at least 12 months Capability of performed 3 glucose measurement per day Levels of glycated hemoglobin (A1C) less than 10% Patients diagnosed of mental disorders Patients included in structured therapeutic health 6 months before the inclusion Patients included in any clinical trial in the 4 months before the inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>